CG Invites Co

CG Invites Co Equity

The The Equity of CG Invites Co (083790.KQ) as of Nov 3, 2026 is 105.15 B KRW. In the previous year, The Equity was 98.52 B KRW — a change of 6.73% (higher).

Equity

105.15 BKRW

YoY

6.73%

Last updated:

In 2025, CG Invites Co's equity was 105.15 B KRW, a 6.73% increase from the 98.52 B KRW equity in the previous year.

The CG Invites Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
184.47 B KRW
Jan 1, 2019
149.05 B KRW
Jan 1, 2020
214.76 B KRW
Jan 1, 2021
207.84 B KRW
Jan 1, 2022
188.28 B KRW
Jan 1, 2023
145.29 B KRW
Jan 1, 2024
98.52 B KRW
Jan 1, 2025
105.15 B KRW
The CG Invites Co Equity history
YEAREquityYoY
105.15 BKRW+6.73%
98.52 BKRW-32.19%
145.29 BKRW-22.83%
188.28 BKRW-9.41%
207.84 BKRW-3.22%
214.76 BKRW+44.09%
149.05 BKRW-19.20%
184.47 BKRW+101.41%
91.59 BKRW+10.14%
83.16 BKRW+15.59%
71.94 BKRW+30.74%
55.03 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG Invites Co Stock analysis

What does CG Invites Co do? CrystalGenomics, Inc. generates revenue through its Finished Pharmaceuticals Manufacturing segment, which produces and sells finished pharmaceuticals. The Pharmaceutical R&D Division provides clinical trial analysis and technical services while also selling new drugs. The company also operates in the real estate leasing business under the segment structure. The Others segment manufactures and sells hot fats and other household items. Revenue streams are derived from pharmaceutical manufacturing, R&D services, real estate leasing, and household product sales. The primary buyers for finished pharmaceuticals include healthcare providers and distributors. Clinical trial analysis and new drug sales target pharmaceutical companies and research institutions. Real estate leasing serves commercial tenants, while hot fats and household items are sold to retail consumers. The company's segments collectively serve diverse markets across healthcare, real estate, and consumer goods. CrystalGenomics, Inc. focuses on therapeutic discovery and development, with its R&D Division driving innovation in new drug sales. The Finished Pharmaceuticals Manufacturing segment ensures steady supply of established products. Real estate leasing and household item sales provide additional revenue streams. The company's business model integrates pharmaceutical production, research, and non-pharmaceutical ventures. CG Invites Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing CG Invites Co's Equity

CG Invites Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding CG Invites Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating CG Invites Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

CG Invites Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in CG Invites Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about CG Invites Co stock

The Equity of CG Invites Co is 105.15 B KRW in 2025.

The Equity of CG Invites Co changed from 98.52 B KRW to 105.15 B KRW, representing a 6.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity CG Invites Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's CG Invites Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CG Invites Co

All Key Metrics — CG Invites Co